CN112153979A - 包含glp-1激动剂和n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐的固体组合物 - Google Patents

包含glp-1激动剂和n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐的固体组合物 Download PDF

Info

Publication number
CN112153979A
CN112153979A CN201980031030.XA CN201980031030A CN112153979A CN 112153979 A CN112153979 A CN 112153979A CN 201980031030 A CN201980031030 A CN 201980031030A CN 112153979 A CN112153979 A CN 112153979A
Authority
CN
China
Prior art keywords
glp
ethoxy
composition
agonist
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980031030.XA
Other languages
English (en)
Chinese (zh)
Inventor
S·布杰雷加尔德
U·莱特·拉贝克
P·乔纳斯·萨塞尼
J·杰伦·沃特
A·维格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN112153979A publication Critical patent/CN112153979A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN201980031030.XA 2018-05-07 2019-05-06 包含glp-1激动剂和n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐的固体组合物 Pending CN112153979A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18171046.8 2018-05-07
EP18171046 2018-05-07
PCT/EP2019/061502 WO2019215063A1 (en) 2018-05-07 2019-05-06 Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid

Publications (1)

Publication Number Publication Date
CN112153979A true CN112153979A (zh) 2020-12-29

Family

ID=62134107

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980031030.XA Pending CN112153979A (zh) 2018-05-07 2019-05-06 包含glp-1激动剂和n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐的固体组合物

Country Status (25)

Country Link
US (2) US11622996B2 (https=)
EP (2) EP3790575B1 (https=)
JP (2) JP7164628B2 (https=)
KR (2) KR20250111399A (https=)
CN (1) CN112153979A (https=)
AR (1) AR115283A1 (https=)
AU (2) AU2019264783B2 (https=)
BR (1) BR112020021717A2 (https=)
CA (1) CA3097944A1 (https=)
CL (1) CL2020002797A1 (https=)
CO (1) CO2020014570A2 (https=)
ES (1) ES3041298T3 (https=)
HR (1) HRP20251112T1 (https=)
HU (1) HUE073123T2 (https=)
IL (2) IL312620A (https=)
MA (1) MA52556B1 (https=)
MX (1) MX2020011308A (https=)
MY (1) MY206098A (https=)
PE (1) PE20211794A1 (https=)
PH (1) PH12020551691A1 (https=)
PL (1) PL3790575T3 (https=)
RS (1) RS67212B1 (https=)
SG (1) SG11202009978WA (https=)
TW (1) TWI829687B (https=)
WO (1) WO2019215063A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113171446A (zh) * 2021-05-06 2021-07-27 合肥天汇孵化科技有限公司 利拉鲁肽组合物及其用途
WO2022268213A1 (zh) * 2021-06-25 2022-12-29 甘李药业股份有限公司 含glp-1化合物的药物组合物

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6672140B2 (ja) 2013-05-02 2020-03-25 ノヴォ ノルディスク アー／エス Ｇｌｐ−１化合物の経口投薬
PL3746111T3 (pl) 2018-02-02 2024-01-15 Novo Nordisk A/S Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową
TWI829687B (zh) * 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CN110642935A (zh) * 2019-09-25 2020-01-03 成都奥达生物科技有限公司 一种替瑞帕肽类似物
CN114641276A (zh) * 2019-11-07 2022-06-17 诺和诺德股份有限公司 包含glp-1激动剂、sglt2抑制剂和n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐的固体组合物
EP4104820A4 (en) 2020-02-14 2024-04-17 G2GBIO, Inc. Pharmaceutical composition comprising sustained-release microspheres including glp-1 analogue or pharmaceutically acceptable salt thereof
EP4142695B1 (en) 2020-04-29 2025-11-05 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and histidine
TWI850611B (zh) 2020-12-18 2024-08-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1及澱粉素受體之共促效劑
WO2023065231A1 (en) * 2021-10-21 2023-04-27 Guangzhou Dazhou Biomedicine Ltd. Oral delivery of therapeutic agents
JP2025517672A (ja) 2022-05-10 2025-06-10 ノヴォ ノルディスク アー／エス プロドラッグおよびその使用
AR129879A1 (es) * 2022-07-08 2024-10-09 Novo Nordisk As Compuestos de isvd altamente potentes capaces de sustituir al fviii(a)
MA71385A (fr) * 2022-07-08 2025-04-30 Novo Nordisk A/S Composés isvd hautement puissants capables de remplacer fviii(a)
WO2024133739A1 (en) 2022-12-22 2024-06-27 Novo Nordisk A/S Amylin receptor agonists
US12116388B2 (en) 2022-12-22 2024-10-15 Novo Nordisk A/S Amylin receptor agonists
TW202511291A (zh) * 2023-09-11 2025-03-16 丹麥商諾佛 儂迪克股份有限公司 抗ｉｌ－６結構域之抗體
JP7755031B2 (ja) 2023-11-30 2025-10-15 ノヴォ ノルディスク アー／エス Ｇｌｐ－１、ｇｉｐ、およびアミリン受容体の三重作動薬

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2525168A1 (en) * 2003-05-14 2004-12-02 Emisphere Technologies, Inc. Compositions for delivering peptide yy and pyy agonists
CN1787830A (zh) * 2003-05-14 2006-06-14 爱密斯菲尔科技公司 用于传送肽yy和pyy激动剂的组合物
US20060286129A1 (en) * 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
CN1968919A (zh) * 2004-04-16 2007-05-23 爱密斯菲尔科技公司 用于递送活性剂的8－（2－羟基苯氧基）辛基二乙醇胺和其盐
WO2008129319A1 (en) * 2007-04-20 2008-10-30 Astrazeneca Ab Salts of oxadiazole derivatives as dgat inhibitors
CN101443028A (zh) * 2004-07-12 2009-05-27 爱密斯菲尔科技公司 用于递送肽yy和pyy激动剂的组合物
CN103260608A (zh) * 2010-12-16 2013-08-21 诺沃—诺迪斯克有限公司 包含glp-1激动剂和n-(8-(2-羟基苯甲酰)氨基)辛酸盐的固体组合物
WO2013189988A1 (en) * 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
CN104203221A (zh) * 2012-03-22 2014-12-10 诺和诺德A/S（股份有限公司） 包含递送剂的组合物及其制备
AU2014261336A1 (en) * 2013-05-02 2015-10-08 Novo Nordisk A/S Oral dosing of GLP-1 compounds
CN106459171A (zh) * 2014-02-28 2017-02-22 诺和诺德股份有限公司 A22K,desB27,B29R,desB30,在赖氨酸22的ε位置处被酰化的人胰岛素类似物
CN107812181A (zh) * 2012-03-22 2018-03-20 诺和诺德股份有限公司 Glp‑1肽组合物及其制备

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3122128B2 (ja) 1989-12-21 2001-01-09 ノボ ノルディスク アクティーゼルスカブ ペプチド製剤
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
EP0796106B1 (en) * 1994-12-23 2003-03-19 Novo Nordisk A/S Protracted glp-1 compositions
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
DE19530865A1 (de) 1995-08-22 1997-02-27 Michael Dr Med Nauck Wirkstoff sowie Mittel zur parenteralen Ernährung
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
EP1061946B1 (en) 1998-02-27 2004-04-28 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
JP2002512175A (ja) 1998-02-27 2002-04-23 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ−１類似体の誘導体類
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
EP1062240B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S N-terminally modified glp-1 derivatives
CN1317967A (zh) 1998-09-17 2001-10-17 伊莱利利公司 蛋白质制剂
CA2361716C (en) 1999-02-05 2009-04-28 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
AU3957400A (en) 1999-04-16 2000-11-02 Novo Nordisk A/S Dry, mouldable drug formulation
WO2001092206A1 (en) 2000-06-02 2001-12-06 Emisphere Technologies, Inc. Method of preparing salicylamides
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
US7144863B2 (en) 2001-06-01 2006-12-05 Eli Lilly And Company GLP-1 formulations with protracted time action
CN1332711C (zh) 2002-02-20 2007-08-22 埃米球科技有限公司 施用glp－1分子的方法
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
MXPA06006745A (es) 2003-12-18 2006-08-18 Novo Nordisk As Compuestos glp-1 novedosos.
JP2007537142A (ja) 2003-12-18 2007-12-20 ノボ　ノルディスク　アクティーゼルスカブ アルブミン様物質に結合した新規のｇｌｐ−１類似物
JP2008537873A (ja) 2004-03-31 2008-10-02 セントカー・インコーポレーテツド ヒトｇｌｐ−１ミメティボディ、組成物、方法および用途
WO2005107773A2 (en) * 2004-05-06 2005-11-17 Emisphere Technologies, Inc. Solid dosage form of wetted heparin
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
MXPA06015049A (es) 2004-07-08 2007-02-08 Novo Nordisk As Marcadores prolongadores de polipeptidos que comprenden una porcion tetrazol.
US8030273B2 (en) 2004-10-07 2011-10-04 Novo Nordisk A/S Protracted exendin-4 compounds
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
EA011166B1 (ru) 2004-12-22 2009-02-27 Эли Лилли Энд Компани Композиции слитых белков-аналогов glp-1
KR20070090036A (ko) 2004-12-22 2007-09-04 센토코 인코포레이티드 Ｇｌｐ-1 작용제, 조성물, 방법 및 용도
ES2540929T3 (es) * 2005-02-01 2015-07-14 Emisphere Technologies, Inc. Sistema de administración de retención gástrica y liberación controlada
JP5755398B2 (ja) 2005-03-18 2015-07-29 ノヴォ ノルディスク アー／エス 伸長されたｇｌｐ−１化合物
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
ES2365410T3 (es) 2005-04-08 2011-10-04 Amylin Pharmaceuticals, Inc. Formulaciones farmacéuticas que comprenden péptido de incretina y un disolvente polar aprótico.
EP1968645A4 (en) 2005-12-22 2009-11-04 Centocor Ortho Biotech Inc HUMAN GLP-1 MIMETIC BODIES AND COMPOSITIONS FOR THE TREATMENT OF ADIPOSITAS AND RELATED DISEASES, METHODS AND APPLICATIONS
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
US8679540B2 (en) 2006-06-09 2014-03-25 Flamel Technologies Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications
AU2007275294A1 (en) 2006-07-18 2008-01-24 Centocor, Inc. Human GLP-1 mimetibodies, compositions, methods and uses
US8501693B2 (en) 2006-08-04 2013-08-06 Amylin Pharmaceuticals, Llc Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
EP2068910A2 (en) 2006-08-04 2009-06-17 Amylin Pharmaceuticals, Inc. Use of exendins and exendin agonists and glp-1 receptor agonists for altering lipoprotein particle size and subclass composition
US20090318353A1 (en) 2006-08-25 2009-12-24 Novo Nordisk A/S Acylated Exendin-4 Compounds
CA2662080C (en) 2006-09-07 2012-07-17 F. Hoffmann-La Roche Ag A process for the manufacture of snac (salcaprozate sodium)
WO2008070547A1 (en) * 2006-12-01 2008-06-12 Emisphere Technologies Inc. Improved acyclovir formulations
TW200843794A (en) 2006-12-21 2008-11-16 Centocor Inc Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles
EP1980245A1 (en) 2007-04-11 2008-10-15 Cephalon France Bilayer lyophilized pharmaceutical compositions and methods of making and using same
US20100080829A1 (en) 2007-04-11 2010-04-01 Cephalon France Lyophilized pharmaceutical compositions and methods of making and using same
WO2009030774A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
US20100261637A1 (en) 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
EP2231191A2 (en) 2007-12-11 2010-09-29 ConjuChem Biotechnologies Inc. Formulation of insulinotropic peptide conjugates
JP2009274983A (ja) 2008-05-14 2009-11-26 Kowa Co ニコチン酸アミドを含有する経口医薬組成物
WO2009158412A2 (en) 2008-06-25 2009-12-30 Endo Pharmaceuticals Solutions Inc. Sustained delivery of exenatide and other polypeptides
RU2494755C2 (ru) 2008-08-18 2013-10-10 Интера Био Лтд. Способы и композиции для перорального введения белков
KR101760953B1 (ko) 2008-09-04 2017-07-24 아밀린 파마슈티칼스, 엘엘씨. 비-수성 담체를 이용한 서방성 제형물
US8425968B2 (en) 2009-06-19 2013-04-23 Pepsico., Inc. Beverage preservative system containing pimaricin-cyclodextrin complex
US20120065255A1 (en) * 2009-10-19 2012-03-15 Nagesh Palepu Cabazitaxel formulations and methods of preparing thereof
NZ599847A (en) 2009-11-13 2013-09-27 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
TR201809460T4 (tr) 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
EP2512518A1 (en) 2009-12-16 2012-10-24 Novo Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
AU2010339907A1 (en) 2009-12-16 2012-07-05 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
CA2790708A1 (en) * 2010-02-24 2011-09-01 Emisphere Technologies, Inc. Oral b12 therapy
WO2011109784A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Formulation of insulinotropic peptide conjugates
EP2637698B1 (en) 2010-11-09 2022-04-20 Novo Nordisk A/S Double-acylated glp-1 derivatives
CN102718858B (zh) 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
RU2602601C2 (ru) 2011-04-12 2016-11-20 Ново Нордиск А/С Дважды ацилированные производные glp-1
US20140220134A1 (en) 2011-06-24 2014-08-07 Astrazeneca Pharamceuticals LP Method for treating diabetes with extended release formulation of glp-1 receptor agonists
JP6006309B2 (ja) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
EP2873422A4 (en) 2012-07-10 2015-12-30 Takeda Pharmaceutical PHARMACEUTICAL PREPARATION FOR INJECTION
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HK1211232A1 (en) 2012-12-21 2016-05-20 Sanofi Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
CN103405753B (zh) 2013-08-13 2016-05-11 上海仁会生物制药股份有限公司 稳定的促胰岛素分泌肽水针药物组合物
WO2015086732A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
US10689429B2 (en) 2014-04-07 2020-06-23 Novo Nordisk A/S Double-acylated GLP-1 compounds
DK3006045T3 (en) 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
CN107205949A (zh) 2015-01-29 2017-09-26 诺和诺德股份有限公司 包含片芯和立即释放包衣的用于口服glp‑1给药的药物组合物
CN107708667A (zh) 2015-06-16 2018-02-16 太阳医药高级研发有限公司 长效利拉鲁肽组合物
EP3359181A1 (en) 2015-10-07 2018-08-15 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide drugs
WO2017149070A1 (en) 2016-03-03 2017-09-08 Novo Nordisk A/S Glp-1 derivatives and uses thereof
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
BR112019008565A2 (pt) * 2016-10-31 2019-07-09 Suda Ltd distribuição do agente ativo na mucosa
AR112015A1 (es) 2017-06-09 2019-09-11 Novo Nordisk As Composiciones sólidas para administración oral
PL3746111T3 (pl) 2018-02-02 2024-01-15 Novo Nordisk A/S Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową
RS63523B1 (sr) 2018-04-05 2022-09-30 Sun Pharmaceutical Ind Ltd Novi glp-1 analozi
TWI829687B (zh) * 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2525168A1 (en) * 2003-05-14 2004-12-02 Emisphere Technologies, Inc. Compositions for delivering peptide yy and pyy agonists
CN1787830A (zh) * 2003-05-14 2006-06-14 爱密斯菲尔科技公司 用于传送肽yy和pyy激动剂的组合物
US20060286129A1 (en) * 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
CN1968919A (zh) * 2004-04-16 2007-05-23 爱密斯菲尔科技公司 用于递送活性剂的8－（2－羟基苯氧基）辛基二乙醇胺和其盐
CN101443028A (zh) * 2004-07-12 2009-05-27 爱密斯菲尔科技公司 用于递送肽yy和pyy激动剂的组合物
WO2008129319A1 (en) * 2007-04-20 2008-10-30 Astrazeneca Ab Salts of oxadiazole derivatives as dgat inhibitors
CN103260608A (zh) * 2010-12-16 2013-08-21 诺沃—诺迪斯克有限公司 包含glp-1激动剂和n-(8-(2-羟基苯甲酰)氨基)辛酸盐的固体组合物
US20130345134A1 (en) * 2010-12-16 2013-12-26 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
CN104203221A (zh) * 2012-03-22 2014-12-10 诺和诺德A/S（股份有限公司） 包含递送剂的组合物及其制备
CN107812181A (zh) * 2012-03-22 2018-03-20 诺和诺德股份有限公司 Glp‑1肽组合物及其制备
WO2013189988A1 (en) * 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
AU2014261336A1 (en) * 2013-05-02 2015-10-08 Novo Nordisk A/S Oral dosing of GLP-1 compounds
CN106459171A (zh) * 2014-02-28 2017-02-22 诺和诺德股份有限公司 A22K,desB27,B29R,desB30,在赖氨酸22的ε位置处被酰化的人胰岛素类似物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
C BEGLINGER等: "Pharmacokinetics and Pharmacodynamic Effects of Oral GLP-1 and PYY3-36: A Proof-of-concept Study in Healthy Subjects", CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 84, no. 4, 31 October 2008 (2008-10-31), pages 468 - 474 *
PURWA JAIN等: "SOLUBILITY ENHANCEMENT TECHNIQUES WITH SPECIALEMPHASIS ON HYDROTROPHY", INTERNATIONAL JOURNAL OF PHARMA PROFESSIONAL’S RESEARCH REVIEW ARTICLE, vol. 1, no. 1, pages 1 - 12 *
VIVIDHA DHAPTE等: "Advances in hydrotropic solutions: An updated review", PHYSICS AND MATHEMATICS 1, pages 424 - 435 *
徐斯盛;张惠斌;周金培;黄建军;: "新型抗糖尿病药物的研究进展", 中国药科大学学报, no. 02, pages 97 - 106 *
臧彦楠;方翼;: "肠促胰岛素相关药物的药代动力学/药效学模型研究进展", 中国临床药理学杂志, no. 02, 28 January 2015 (2015-01-28), pages 146 - 149 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113171446A (zh) * 2021-05-06 2021-07-27 合肥天汇孵化科技有限公司 利拉鲁肽组合物及其用途
CN113171446B (zh) * 2021-05-06 2022-03-29 合肥天汇孵化科技有限公司 利拉鲁肽组合物及其用途
WO2022268213A1 (zh) * 2021-06-25 2022-12-29 甘李药业股份有限公司 含glp-1化合物的药物组合物

Also Published As

Publication number Publication date
EP3790575B1 (en) 2025-07-30
AU2025204852A1 (en) 2025-07-24
TWI829687B (zh) 2024-01-21
KR20210008353A (ko) 2021-01-21
IL277857B2 (en) 2024-10-01
JP7529743B2 (ja) 2024-08-06
PL3790575T3 (pl) 2025-11-17
CA3097944A1 (en) 2019-11-14
MX2020011308A (es) 2020-11-18
BR112020021717A2 (pt) 2021-01-26
KR102835312B1 (ko) 2025-07-18
AR115283A1 (es) 2020-12-16
MA52556A (fr) 2021-03-17
CL2020002797A1 (es) 2021-02-19
IL277857B1 (en) 2024-06-01
MA52556B1 (fr) 2025-09-30
WO2019215063A1 (en) 2019-11-14
EP4674479A3 (en) 2026-01-28
TW202015722A (zh) 2020-05-01
AU2019264783B2 (en) 2025-04-03
ES3041298T3 (en) 2025-11-11
SG11202009978WA (en) 2020-11-27
EP3790575C0 (en) 2025-07-30
JP2021523149A (ja) 2021-09-02
JP7164628B2 (ja) 2022-11-01
PE20211794A1 (es) 2021-09-09
US11622996B2 (en) 2023-04-11
US20230087952A1 (en) 2023-03-23
KR20250111399A (ko) 2025-07-22
HRP20251112T1 (hr) 2025-11-07
IL277857A (en) 2020-11-30
AU2019264783A1 (en) 2020-12-10
US20210236601A1 (en) 2021-08-05
HUE073123T2 (hu) 2026-01-28
PH12020551691A1 (en) 2021-07-19
JP2022191439A (ja) 2022-12-27
IL312620A (en) 2024-07-01
EP4674479A2 (en) 2026-01-07
WO2019215063A8 (en) 2020-07-02
RS67212B1 (sr) 2025-10-31
CO2020014570A2 (es) 2021-03-08
EP3790575A1 (en) 2021-03-17
MY206098A (en) 2024-11-28

Similar Documents

Publication Publication Date Title
JP7529743B2 (ja) Ｇｌｐ－１アゴニストとｎ－（８－（２－ヒドロキシベンゾイル）アミノ）カプリル酸の塩とを含む固体組成物
CN111683676B (zh) 包含glp-1激动剂、n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐和润滑剂的固体组合物
US20220265777A1 (en) Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
CN115461044A (zh) 包含glp-1激动剂和组氨酸的固体组合物
RU2804318C2 (ru) Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
HK40039302B (en) Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino) caprylic acid
HK40039302A (en) Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino) caprylic acid

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination